Antibody-Drug Conjugates Marketplace Examined in La Merie Publishing Report Recently Published at MarketPublishers.com
09 Dec 2015 • by Natalie Aster
LONDON – At present, approximately 70 antibody-drug conjugates are in pre-IND or clinical stages of development.
Combined sales of marketed ADC products (Kadcyla and Adcetris) are set to exceed the sales limit of USD 1 billion for the first time in 2015. Some new ADCs are expected to receive approval in the near term or in the mid-term.
A large number of prominent biotech and pharma players have ADC programs, with their strategies of how to gain ADC technologies being different.
In-demand research report “Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis” drawn up by La Merie Publishing offers a comprehensive analysis of the situation in the global market for antibody-drug conjugates. The study provides thorough examination of the ADC pipeline. It sheds light on ADC technologies and investigates the competitive landscape. The report explores commercial opportunities and perspectives with the conjugates. The research study contains detailed ADC drug and company profiles.
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Published: November, 2015
Price: US$ 2,590.00
- Insightful overview of the marketplace;
- Coverage of Next-to-market ADCs;
- Data on commercialization of approved ADCs;
- Information on pharma and biotech companies having ADC programs;
- Details on ADC Development Failures;
- And more.
More cutting-edge studies on different markets by the publisher can be found at La Merie Publishing page.